The demo realized the two its Main endpoints, with semaglutide two.four mg demonstrating statistically important and top-quality advancements in liver fibrosis with no worsening of steatohepatitis, and also resolution of steatohepatitis without worsening of liver fibrosis in people with MASH in comparison with placebo.1The next critical adverse rea